{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:18:59Z","timestamp":1784121539065,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011957","name":"Takeda Pharmaceutical Company Limited | Takeda Oncology","doi-asserted-by":"publisher","award":["Millennium Grant X25001"],"award-info":[{"award-number":["Millennium Grant X25001"]}],"id":[{"id":"10.13039\/100011957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","award":["Millennium Grant X25001"],"award-info":[{"award-number":["Millennium Grant X25001"]}],"id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1038\/s41375-021-01386-z","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T12:10:57Z","timestamp":1629288657000},"page":"580-582","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group"],"prefix":"10.1038","volume":"36","author":[{"given":"Carla","family":"Damaschin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Goergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Kreissl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Pl\u00fctschow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Breywisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9626-1413","authenticated-orcid":false,"given":"Stephan","family":"Mathas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Meissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"S\u00f6kler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max S.","family":"Topp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladan","family":"Vucinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1927-3514","authenticated-orcid":false,"given":"Dennis A.","family":"Eichenauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,18]]},"reference":[{"key":"1386_CR1","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","volume":"379","author":"A Engert","year":"2012","unstructured":"Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379:1791\u20139.","journal-title":"Lancet"},{"key":"1386_CR2","doi-asserted-by":"publisher","unstructured":"Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, et al. PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2017. https:\/\/doi.org\/10.1016\/S0140-6736(17)32134-7.","DOI":"10.1016\/S0140-6736(17)32134-7"},{"key":"1386_CR3","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.3324\/haematol.2017.167478","volume":"102","author":"DA Eichenauer","year":"2017","unstructured":"Eichenauer DA, Becker I, Monsef I, Chadwick N, de Sanctis V, Federico M, et al. Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials. Haematologica. 2017;102:1748\u201357.","journal-title":"Haematologica"},{"key":"1386_CR4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2012.44.3721","volume":"31","author":"K Behringer","year":"2013","unstructured":"Behringer K, Mueller H, Goergen H, Thielen I, Eibl AD, Stumpf V, et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol. 2013;31:231\u20139.","journal-title":"J Clin Oncol"},{"key":"1386_CR5","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/S1470-2045(17)30696-4","volume":"18","author":"DA Eichenauer","year":"2017","unstructured":"Eichenauer DA, Plutschow A, Kreissl S, Sokler M, Hellmuth JC, Meissner J, et al. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin\u2019s lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. Lancet Oncol. 2017;18:1680\u20137.","journal-title":"Lancet Oncol"},{"key":"1386_CR6","doi-asserted-by":"publisher","unstructured":"Straus DJ, D\u0142ugosz-Danecka M, Alekseev S, Ill\u00e9s \u00c1, Picardi M, Lech-Maranda E, et al. Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood 2020;135. https:\/\/doi.org\/10.1182\/blood.2019003127.","DOI":"10.1182\/blood.2019003127"},{"key":"1386_CR7","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1182\/blood-2013-07-512657","volume":"123","author":"DA Eichenauer","year":"2014","unstructured":"Eichenauer DA, Thielen I, Haverkamp H, Franklin J, Behringer K, Halbsguth T, et al. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood. 2014;123:1658\u201364.","journal-title":"Blood"},{"key":"1386_CR8","doi-asserted-by":"publisher","first-page":"e462","DOI":"10.1016\/S2352-3026(18)30140-6","volume":"5","author":"B von Tresckow","year":"2018","unstructured":"von Tresckow B, Kreissl S, Goergen H, Brockelmann PJ, Pabst T, Fridrik M, et al. Intensive treatment strategies in advanced-stage Hodgkin\u2019s lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. Lancet Haematol. 2018;5:e462\u2013e473.","journal-title":"Lancet Haematol"},{"key":"1386_CR9","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1200\/JCO.2012.44.5791","volume":"31","author":"MZ Koontz","year":"2013","unstructured":"Koontz MZ, Horning SJ, Balise R, Greenberg PL, Rosenberg SA, Hoppe RT, et al. Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. J Clin Oncol. 2013;31:592\u20138.","journal-title":"J Clin Oncol"},{"key":"1386_CR10","doi-asserted-by":"publisher","unstructured":"Eichenauer DA, M\u00fcller H, Elger L, Goergen H, Fuchs M, Kreissl S, et al. Non\u2010Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study Group. Br J Haematol. 2021;193. https:\/\/doi.org\/10.1111\/bjh.17327.","DOI":"10.1111\/bjh.17327"},{"key":"1386_CR11","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.1200\/JCO.2011.34.8268","volume":"29","author":"AJ Swerdlow","year":"2011","unstructured":"Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, et al. Second cancer risk after chemotherapy for Hodgkin\u2019s lymphoma: a collaborative British cohort study. J Clin Oncol. 2011;29:4096\u2013104.","journal-title":"J Clin Oncol"},{"key":"1386_CR12","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","volume":"373","author":"M Schaapveld","year":"2015","unstructured":"Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, et al. Second cancer risk up to 40 years after treatment for Hodgkin\u2019s Lymphoma. N Engl J Med. 2015;373:2499\u2013511.","journal-title":"N Engl J Med"},{"key":"1386_CR13","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","volume":"374","author":"P Johnson","year":"2016","unstructured":"Johnson P, Federico M, Kirkwood A, Fossa A, Berkahn L, Carella A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s Lymphoma. N Engl J Med. 2016;374:2419\u201329.","journal-title":"N Engl J Med"},{"key":"1386_CR14","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"JM Connors","year":"2018","unstructured":"Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s Lymphoma. N Engl J Med. 2018;378:331\u201344.","journal-title":"N Engl J Med"},{"key":"1386_CR15","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S1470-2045(16)30093-6","volume":"17","author":"S Kreissl","year":"2016","unstructured":"Kreissl S, Mueller H, Goergen H, Mayer A, Brillant C, Behringer K, et al. Cancer-related fatigue in patients with and survivors of Hodgkin\u2019s lymphoma: a longitudinal study of the German Hodgkin Study Group. Lancet Oncol. 2016;17:1453\u201362.","journal-title":"Lancet Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01386-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01386-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01386-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T09:04:34Z","timestamp":1643706274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01386-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1386"],"URL":"https:\/\/doi.org\/10.1038\/s41375-021-01386-z","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,18]]},"assertion":[{"value":"7 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BvT is an advisor or consultant for Amgen, BMS\/Celgene, Novartis, Pentixafarm, Pfizer, Takeda, Merck Sharp & Dohme, and Gilead Kite; has received honoraria from Novartis, Roche Pharma AG, Takeda, and Merck Sharp & Dohme; reports research funding from Novartis (Inst), Merck Sharp & Dohme (Inst), and Takeda (Inst); and reports travel support from AbbVie, AstraZeneca, KiteGilead, Merck Sharp & Dohme, Takeda, and Novartis. AZ has received honoraria from Takeda; and reports travel grants from Takeda. All other authors report no potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}